SCHEMBL4626748

SCHEMBL4626748

Cc1cc(C(=O)O)c(C(=O)O)cc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.45
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
LCK P06239 1/20 0.45
FYN P06241 1/20 0.45
GAA P10253 1/20 0.45
AKR1C4 P17516 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
NOTUM Q6P988 1/20 0.43
MYC P01106 2/20 0.42
TSHR P16473 1/20 0.41
ALDH1A1 P00352 3/20 0.40
HMGB1 P09429 1/20 0.39
CXCL12 P48061 1/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2796102 0.88 HSD17B10 (0.44) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL155337 0.88 LCK (0.44) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL2537783 0.88 LCK (0.53) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL29693917 0.88 LCK (0.44) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL5154168 0.87 LCK (0.44) HSD17B10KDM4EHPGDLCKFYN
Hydrochloric Acid SCHEMBL7670687 0.86 HSD17B10 (0.42) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL167694 0.85 GRM1 (0.51) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL1728791 0.85 ALDH1A1 (0.49) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL26841753 0.84 LCK (0.53) HSD17B10KDM4EHPGDLCKFYN
SCHEMBL25300915 0.83 CA12 (0.46) HSD17B10KDM4EHPGDLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
WO-2025041076-A1 BICYCLIC COMPOUNDS AS CDK INHIBITORS BEIGENE SWITZERLAND GMBH (CH) 2025-02-27 WO disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
CN-116813468-A 4-halogeno-5-substituted phthalic acid and preparation method thereof 中国石油化工股份有限公司 2023-09-29 CN disclosed
CN-116803970-A 6,6' -disubstituted-3, 3', 4' -biphenyl tetracarboxylic acid and dianhydride thereof and preparation method thereof 中国石油化工股份有限公司 2023-09-26 CN disclosed
CN-116789543-A Preparation method of 4-halogenated-5-substituted phthalic acid and product and application thereof 中国石油化工股份有限公司 2023-09-22 CN disclosed
WO-2022246179-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2022-11-24 WO disclosed
EP-1209172-B1 SOLID CATALYST COMPONENT AND CATALYST FOR OLEFIN POLYMERIZATION TOHO TITANIUM CO LTD (JP) 2008-07-02 EP disclosed
EP-1013650-B1 Tetracarboxylic dianhydride, derivative and production thereof, polyimide precursor, polyimide, resin composition, photosensitive resin composition, method of forming relief pattern, and electronic part HITACHI CHEM DUPONT MICROSYS (JP) 2007-01-24 EP disclosed
US-6600053-B2 Useful for producing polyimide precursors or polyimides having low thermal expansion and low residual stress HITACHI CHEMICAL DUPONT MICROSYSTEMS LTD. (JP) 2003-07-29 US disclosed
US-20020037991-A1 Photosensitive resin composition HITACHI CHEMICAL DUPONT MICROSYSTEMS LTD. (JP) 2002-03-28 US disclosed
US-6329494-B1 HIGH-SPEED DEVELOPABILITY, HIGH RESOLUTION AND GOOD DIMENSIONAL ACCURACY TO SUIT THEM TO THE PRODUCTION OF INTERLAYER INSULATING FILMS OR SURFACE-PROTECTING FILMS IN SEMICONDUCTOR DEVICES HITACHI CHEMICAL DUPONT MICROSYSTEMS LTD. (JP) 2001-12-11 US disclosed
EP-1013650-A2 Tetracarboxylic dianhydride, derivative and production thereof, polyimide precursor, polyimide, resin composition, photosensitive resin composition, method of forming relief pattern, and electronic part Hitachi Chemical DuPont MicroSystems Ltd. (JP) 2000-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226115-A1 AXL INHIBITOR COMPOUNDS AXL, BTK, MERTK HSD17B10 4579/4885KDM4E 2046/4885HPGD 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.